SCHEMBL2912299

SCHEMBL2912299

COC(=O)CC1C[N]CCCN1C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.36
DRD1 P21728 1/20 0.33
HRH2 P25021 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
OPRK1 P41145 1/20 0.33
HTR2B P41595 1/20 0.33
KCNH2 Q12809 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
CHRNB2 P17787 2/20 0.31
CHRNA5 P30532 2/20 0.31
CHRNA7 P36544 2/20 0.31
CHRNA4 P43681 2/20 0.31
CHRM3 P20309 3/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MCHR1 Q99705 2/20 0.30
MIF P14174 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2915538 0.90 BRD4 (0.37) BRD4DRD1HRH2HTR2AHTR2C
SCHEMBL2919711 0.85 POLB (0.35) SMN1; SMN2CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL2913123 0.82 TSHR (0.35) CHRNB2CHRNA5CHRNA7CHRNA4CHRM3
SCHEMBL4088779 0.78 CHRNB2 (0.44) BRD4CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL4088784 0.78 CHRNB2 (0.44) BRD4CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL2911063 0.78
SCHEMBL24872393 0.77 CYP1A2 (0.44) BRD4DRD1HRH2HTR2AHTR2C
Hydrochloric Acid SCHEMBL21801537 0.77 CHRNB2 (0.43) BRD4CHRNB2CHRNA5CHRNA7CHRNA4
SCHEMBL2918986 0.76 BRD4 (0.36) BRD4SMN1; SMN2KMT2AMIF
SCHEMBL2917560 0.75 GAA (0.34) SMN1; SMN2KMT2AMIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 BRD4 848/4885DRD1 2293/4885HRH2 415/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 BRD4 500/4885DRD1 3780/4885HRH2 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.